July 26, 2024

Efficacy of Oral Semaglutide in Early-Stage Diabetes: Insights from a New Italian Study

Semaglutide, a GLP-1 agonist, is commonly used to treat diabetes, cardiovascular health issues, and facilitate weight loss. Traditionally administered via injection, semaglutide mimics the glucagon-like peptide-1 hormone, stimulating insulin release and slowing gastric emptying to promote satiety.

Study Findings on Oral Semaglutide

A new clinical trial in Italy has investigated the efficacy of oral semaglutide, particularly in patients with early-stage diabetes. The study, published in the Journal of Clinical Medicine, highlights that oral semaglutide is most beneficial for those recently diagnosed with diabetes. These patients showed significant improvements in HbA1c levels (a measure of blood sugar) and body weight. However, the study noted that oral semaglutide is less effective than its injectable counterparts in other patients.

Challenges with Oral Administration

Oral semaglutide requires significantly larger doses than injectables due to lower bioavailability; less of the drug reaches the bloodstream, which may reduce its effectiveness. Despite this, it offers a valuable alternative for patient preferences and circumstances, such as concerns over injectable drug shortages.

Comparative Effectiveness

The typical dosing for injectable semaglutide, such as Ozempic and Wegovy, ranges from 0.25 mg to 2.4 mg per week. In contrast, participants in the Italian study were given daily doses of oral semaglutide starting at 3 mg and increasing to 7 mg, with some receiving up to 14 mg daily. The study found that even at these higher doses, the drug was generally well tolerated.

Broader Implications and Future Directions

Oral semaglutide, like the currently available Rybelsus, may serve as a viable alternative for patients, particularly those newly diagnosed with diabetes. However, further research is needed to fully assess its long-term efficacy and cardiovascular benefits, with ongoing studies such as the SOUL trial expected to provide more insights.

Expert Opinions

Experts like Dr. Vanita R. Aroda from Brigham and Women's Hospital and Dr. Andrew Hogan from Maynooth University emphasize the importance of having both oral and injectable options to accommodate patient needs. They note that while injectable semaglutide remains more effective, oral formulations could enhance accessibility and patient adherence, especially among adolescents and those wary of injections.